Core Viewpoint - The company has successfully included its innovative enzyme replacement therapy, CAN 103, in China's first version of the "Commercial Insurance Innovative Drug Directory," effective from January 1, 2026, marking a significant milestone for the group [1] Group 1: Product Development - CAN 103 is the first domestically developed enzyme replacement therapy in China, approved for use in adolescents aged 12 and above and adults with Type I and III Gaucher disease [1] - The drug was approved for market launch on May 13, 2025, and is recognized as the first innovative biological drug in China to pass the segmented production inspection for biological products [1] Group 2: Clinical Application - On July 2, 2025, CAN 103 was prescribed for the first time at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, indicating its official entry into clinical use [1] - The introduction of CAN 103 is expected to significantly enhance the accessibility of medication for domestic patients [1] Group 3: Market Impact - The inclusion of CAN 103 in the insurance directory ensures that Gaucher disease patients will have access to safe and effective domestic enzyme replacement therapy, providing broader and more comprehensive treatment coverage [1]
北海康成-B(01228)自主研发生产的CAN 103获纳入中国第一版“商保创新药目录”